Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Type 2 Diabetes Mellitus: Update Bulletin [December 2016]

Product Code:
596200701
Publication Date:
December 2016
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in type 2 diabetes mellitus (T2DM): positive results from AstraZeneca’s Phase III DURATION-8 study which assessed Bydureon (exenatide extended-release), a glucagon-like peptide-1 (GLP-1) receptor agonist, in combination with Forxiga (dapagliflozin) the sodium glucose co-transporter-2 (SGLT2) inhibitor; a recommendation for approval of Boehringer Ingelheim’s and Eli Lilly’s Glyxambi (empagliflozin/linagliptin) by the European Medicines Agency CHMP; and positive data from Merck & Co.’s and Pfizer’s Phase III VERTIS SITA2 study for ertugliflozin in combination with sitagliptin and metformin.

Business Questions:

  • What do KOLs think about the data from the Phase III DURATION-8 study for Bydureon (exenatide) in combination with Forxiga (dapagliflozin)?
  • How do experts view SGLT-2/GLP-1 combination therapy as a strategy for diabetics?
  • How do KOLs think Bydureon and Forxiga will fare against Jardiance and Victoza?
  • Are fixed-dose combination products of a GLP-1 agonist with SGLT-2 inhibitor on the horizon? What are the challenges?
  • What are KOLs opinions on the approval of Glyxambi in Europe? 
  • How do KOLs view Glyxambi and where is it likely to fit in the treatment strategy?
  • Is Glyxambi going to gain market traction; what do KOLs think?
  • What do KOLs think of Merck & Co.’s pipeline SDLT2 inhibitor, ertugliflozin?
  • Will ertugliflozin based combinations be able to compete and what barriers are they likely to face?



customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved